• Home
  • NEW DAY MEDICINE
  • 10 (60) 2023
  • 89 -10 (60) 2023 — Yuldasheva D.Х., Radjabov N.G. — DIAGNOSTIC VALUE OF CLINICAL AND LABORATORY MARKERS IN NON-ALCOHOLIC FATTY LIVER DISEASE

89 -10 (60) 2023 — Yuldasheva D.Х., Radjabov N.G. — DIAGNOSTIC VALUE OF CLINICAL AND LABORATORY MARKERS IN NON-ALCOHOLIC FATTY LIVER DISEASE

DIAGNOSTIC VALUE OF CLINICAL AND LABORATORY MARKERS IN NON-ALCOHOLIC FATTY LIVER DISEASE

Yuldasheva D.Х., Bukhara State Medical Institute named after Abu Ali ibn Sina

Radjabov N.G. Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This article studied clinical and laboratory analyzes of 98 patients with non-alcoholic fatty liver disease (NAFLD). With steatohepatitis, higher ALT and AST values ​​are noted than in patients with hepatic steatosis. The main differential difference between non-alcoholic steatosis and steatohepatitis, available in clinical practice, may be the severity of the biochemical syndrome of cytolysis. The article contains clinical features and prognosis in patients with fatty hepatosis and non-alcoholic steatohepatitis (NASH). Dyslipidemia (hypertriglyceridemia, decreased HDL, increased LDL) occurs in about 65-85% of patients. The basal insulin level, according to the results of our studies, in persons with NAFLD at the stage of steatosis and steatohepatitis was significantly increased.

Key words: non-alcoholic fatty liver disease, liver steatosis, non-alcoholic steatohepatitis, insulin resistance, obesity, lipoprotein, cholesterol, alanine aminotransferase.

First page

526

Last page

533

For citation: Yuldasheva D.Х., Radjabov N.G. – DIAGNOSTIC VALUE OF CLINICAL AND LABORATORY MARKERS IN NON-ALCOHOLIC FATTY LIVER DISEASE //New Day in Medicine 2023 10(60): 526-533 https://newdaymedicine.com/index.php/2023/12/01/l-553/

LIST OF REFERENCES:

  1. Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования наблюдения DIREGL 01903) // Рос журн гастроэнтерол гепатол колопроктол. 2014;24(4):32-36.
  2. Aijaz Ahmed M.D. Ryan B., Perumpail M.D., Stephen A., Harrison M.D. Hige prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population? // Hepatology. 2016;63(1):20 – 22. doi:10.1002/hep.28277.
  3. Blachier M. Leleu H., Peck Radozavljevic M., Valva D.C., Roudot Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data // J. Hepatol. 2013;58:593-608.
  4. Byrne C.D., Targher G. NAFLD: A multisystem disease // J. of Hepatology. 2015;62:47-64.
  5. Doycheva I. Cui P., Nguyen E.A., Costa J., Hoocer H., Hoffich R., Bettencourt S., Brouha C.B., Sirlin R. Loomba Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE // Aliment. Pharmacol. Ther. 2016;43(1):83-95.
  6. Krivosheev A.B., Kuimov A.D., and et al. Disorders of lipid metabolism peculiarities in nonalcoholic fatty liver disease // Siberian Medical Review 04, 2016;4:48-57.
  7. Micolasevic I., Orlic L., Franjic N., Hauser G., Stimac D. Milic Transient elastography (FibroScan) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease – Were du we stand? / I. Micolasevic, L. Orlic, N. Franjic, G. Hauser, D. Stimac, S. Milic // World J. Gastroenterol. 2016;22(32):7236-7251.
  8. Minnullina Z.Sh. Clinical – diagnostic value of bile acids in blood serum in liver stetosis // Abstract of thesis. dis. PhD. Sciences: 14.00.05 /Minnullina Z.Sh – Kazan, 2018;24.
  9. Podymova S.D. Modern view of the pathogenesis and the problem of treatment of non-alcoholic fatty liver disease // Experimental and clinical gastroenterology. 2016;5:74-82.
  10. Xamrayev А.А., Yuldosheva D.X., Zokirov V.Z., Muxammedova Z.R. Clinical-laboratory markers of progression of non-alcoholic fatty liver disease // American Journal of Medicine and Medical Sciences. – USA, 2021;11(5):419-425.
  11. Xamrayev А.А., Yuldosheva D.X., Шамсиева Т.Т., Хайдаров Д.Б. Diagnostic significance of molecular-genetic markers in the development of non-alcoholic fatty liver disease // New day in medicine Tashkent 2022;9(47):374-381.
  12. Yuldasheva D.H. Shadjanova N.S., Oltiboyev R.O.Non-alcoholic fatty liver disease and modern medicine // Academicia an international multidisciplinary research journal 2020;10(11):1931-1937.
  13. Yuldasheva D.H., Zokirov V.Z., G`ulomova Sh.Q. Non-alcoholic fatty liver disease: Modern view of the problem // A Multidisciplinary Peer Reviewed Journal. 2020;6(12):286-292.
  14. Yuldosheva D.X. Diagnostic significance of laboratory markers, inflammatory and anti – inflammatory cytokines in the development of non-alcoholic fatty liver disease steatosis and steatohepatitis // British Medical Journal, 2022;3:26-35.
  15. Yuldosheva D.X. Prevalence of non- alcoholic fatty liver disease,
    clinical and laboratory markers // Eurasian journal of medical and natural sciences. Tashkent. 2022; 94-100.
  16. Yuldosheva D.X. Reletionship to the refluxate type of the effectiveness of treatment degree of gastroesophageal reflux disease // European Journal of Research. Austria, Vienna. 2019;2:110-114.
  17. Yuldosheva D.X., Zokirov V.Z., G`ulomova Sh.Q. Non-alcoholic fatty liver: modern view of the problem // Multidisciplinary Peer reviewed journal. India. 2020;6(12):286-292.

file

download